BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-384. [PMID: 20113825 DOI: 10.1016/s0140-6736(09)61964-4] [Cited by in Crossref: 771] [Cited by in F6Publishing: 307] [Article Influence: 64.3] [Reference Citation Analysis]
Number Citing Articles
1 Baker GM, King TA, Schnitt SJ. Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. Adv Anat Pathol 2019;26:221-34. [PMID: 31149907 DOI: 10.1097/PAP.0000000000000237] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
2 Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nat Commun 2019;10:657. [PMID: 30737380 DOI: 10.1038/s41467-019-08593-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
3 Holmes FA, Hellerstedt BA, Pippen JE Jr, Vukelja SJ, Collea RP, Kocs DM, Blum JL, McIntyre KJ, Barve MA, Brooks BD, Osborne CR, Wang Y, Asmar L, O'Shaughnessy J. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer. Cancer Med 2018;7:2288-98. [PMID: 29582557 DOI: 10.1002/cam4.1472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Wu YT, Xu Z, Arshad B, Wu JS, Zhang K, Wu H, Li X, Li H, Li YC, Wang ZL, Wu KN, Kong LQ. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials. J Cancer 2018;9:3168-76. [PMID: 30210640 DOI: 10.7150/jca.24701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16-32. [PMID: 22124364 DOI: 10.1038/nrclinonc.2011.177] [Cited by in Crossref: 531] [Cited by in F6Publishing: 493] [Article Influence: 48.3] [Reference Citation Analysis]
6 Stucci LS, Pisino M, D’addario C, Grassi T, Toss A. Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. Front Oncol 2022;12:871160. [DOI: 10.3389/fonc.2022.871160] [Reference Citation Analysis]
7 Gunasekara ADM, Anothaisintawee T, Youngkong S, Ha NT, Mckay GJ, Attia J, Thakkinstian A. Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. Cancers 2022;14:523. [DOI: 10.3390/cancers14030523] [Reference Citation Analysis]
8 Zhou P, Jiang YZ, Hu X, Sun W, Liu YR, Liu F, Luo RC, Shao ZM. Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China. Onco Targets Ther 2016;9:2287-95. [PMID: 27143924 DOI: 10.2147/OTT.S97583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 537] [Cited by in F6Publishing: 490] [Article Influence: 67.1] [Reference Citation Analysis]
10 Ahn ER, Wang E, Glück S. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) 2012;6:191-207. [PMID: 23226023 DOI: 10.4137/BCBCR.S9301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer 2021;20:151. [PMID: 34839818 DOI: 10.1186/s12943-021-01438-z] [Reference Citation Analysis]
12 Mohan A, Ponnusankar S. Newer therapies for the treatment of metastatic breast cancer: a clinical update. Indian J Pharm Sci 2013;75:251-61. [PMID: 24082340 DOI: 10.4103/0250-474X.117396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
13 Alzahrani W, Althoubaity F, Alsobhi D, Mohamed Y, AlMutairi A, Sindi D, Alharbi R, Zaidi N. Clinicopathological Features and Metastatic Pattern of Triple-positive Breast Cancer Among Female Patients at a Tertiary Care Hospital. Cureus 2019;11:e6458. [PMID: 31897358 DOI: 10.7759/cureus.6458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123-40. [PMID: 26712595 DOI: 10.1007/s11739-015-1362-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
15 Sun J, Chen C, Yao X, Sun S. Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials. Oncol Lett 2015;9:1351-8. [PMID: 25663912 DOI: 10.3892/ol.2015.2848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
16 Gollamudi J, Parvani JG, Schiemann WP, Vinayak S. Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res 2016;8:21-31. [PMID: 26937204 DOI: 10.2147/CMAR.S55279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
17 Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol 2022;14:175883592211132. [DOI: 10.1177/17588359221113269] [Reference Citation Analysis]
18 Younis T, Lee A, Coombes ME, Bouganim N, Becker D, Revil C, Jhuti GS. Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada. Curr Oncol 2020;27:e578-89. [PMID: 33380873 DOI: 10.3747/co.27.6517] [Reference Citation Analysis]
19 Brzezinska M, Dixon JM. Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy. Gland Surg 2018;7:520-4. [DOI: 10.21037/gs.2018.08.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Fujii S, Yamashita S, Yamaguchi T, Takahashi M, Hozumi Y, Ushijima T, Mukai H. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. Oncotarget 2017;8:19039-48. [PMID: 28186977 DOI: 10.18632/oncotarget.15118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
21 DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res 2015;21:2911-5. [PMID: 25712686 DOI: 10.1158/1078-0432.CCR-14-1760] [Cited by in Crossref: 55] [Cited by in F6Publishing: 32] [Article Influence: 7.9] [Reference Citation Analysis]
22 McArthur HL, Hudis CA. Chemotherapy: Neoadjuvant trial design: time for a brave new world? Nat Rev Clin Oncol 2010;7:359-60. [PMID: 20592708 DOI: 10.1038/nrclinonc.2010.85] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019;37:2206-2216. [PMID: 31157583 DOI: 10.1200/jco.19.00882] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
24 Wilson FR, Coombes ME, Brezden-Masley C, Yurchenko M, Wylie Q, Douma R, Varu A, Hutton B, Skidmore B, Cameron C. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev 2018;7:191. [PMID: 30428932 DOI: 10.1186/s13643-018-0854-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
25 Mohamed MM, Al-Raawi D, Sabet SF, El-Shinawi M. Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res 2014;5:525-36. [PMID: 25685520 DOI: 10.1016/j.jare.2013.06.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
26 Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 2011;17:952-8. [PMID: 21248299 DOI: 10.1158/1078-0432.CCR-09-1947] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
27 Stevens W, Farrow IM, Georgiou L, Hanby AM, Perren TJ, Windel LM, Wilson DJ, Sharma N, Dodwell D, Hughes TA, Dall BJ, Buckley DL. Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response. Br J Radiol 2021;94:20201396. [PMID: 34106751 DOI: 10.1259/bjr.20201396] [Reference Citation Analysis]
28 Syrios J, Pappa E, Volakakis N, Grivas A, Alafis J, Manioudaki S, Tzouda V, Korogiannos A, Rapti C, Koufopoulos N, Nikolaidou A, Kanavou E, Alexopoulos A, Koumarianou A. Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab. Breast Cancer (Auckl) 2018;12:1178223418758031. [PMID: 29511355 DOI: 10.1177/1178223418758031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
29 Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clin Breast Cancer 2016;16:113-22.e1. [PMID: 26774497 DOI: 10.1016/j.clbc.2015.11.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
30 Mamouch F, Berrada N, Aoullay Z, El Khanoussi B, Errihani H. Inflammatory Breast Cancer: A Literature Review. World J Oncol 2018;9:129-35. [PMID: 30524636 DOI: 10.14740/wjon1161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL. Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer 2015;3:41. [PMID: 26380087 DOI: 10.1186/s40425-015-0084-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
32 Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol 2019;84:839-47. [PMID: 31428820 DOI: 10.1007/s00280-019-03920-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
33 Nodehi RS, Kalantari B, Raafat J, Ansarinejad N, Moazed V, Mortazavizadeh SMR, Hosseinzadeh M, Ghaderi B, Jenabian A, Qadyani M, Haghighat S, Allahyari A, Mirzania M, Seghatoleslami M, Payandeh M, Alikhasi A, Kafi H, Shahi F. A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients. BMC Pharmacol Toxicol 2022;23:57. [PMID: 35902898 DOI: 10.1186/s40360-022-00599-x] [Reference Citation Analysis]
34 Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun 2020;11:5824. [PMID: 33203854 DOI: 10.1038/s41467-020-19494-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
35 Cho DH, Lee SK, Kim S, Choi MY, Jung SP, Lee J, Kim J, Koo MY, Bae SY, Kim JH, Kim JS, Ho KW, Lee JE, Nam SJ, Yang JH. Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer. J Korean Surg Soc 2013;84:273-80. [PMID: 23646312 DOI: 10.4174/jkss.2013.84.5.273] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Stickeler E, Fehm T. Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? Breast Care (Basel) 2014;9:161-7. [PMID: 25177257 DOI: 10.1159/000365129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol 2016;7:356. [PMID: 27766079 DOI: 10.3389/fphar.2016.00356] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
38 Yan H, Xiao H, Zhu J, Zhang J, Liu Z. Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Cancer Manag Res 2020;12:12715-22. [PMID: 33328766 DOI: 10.2147/CMAR.S278694] [Reference Citation Analysis]
39 Chainitikun S, Espinosa Fernandez JR, Long JP, Iwase T, Kida K, Wang X, Saleem S, Lim B, Valero V, Ueno NT. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One 2021;16:e0250057. [PMID: 33861773 DOI: 10.1371/journal.pone.0250057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Díaz-Casas SE, Castilla-Tarra JA, Pena-Torres E, Orozco-Ospino M, Mendoza-Diaz S, Nuñez-Lemus M, Garcia-Angulo O, Garcia-Mora M, Guzman-AbiSaab L, Lehmann-Mosquera C, Angel-Aristizabal J, Duarte-Torres C, Vergel-Martinez JC. Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort. Oncologist 2019;24:e1360-70. [PMID: 31346133 DOI: 10.1634/theoncologist.2019-0300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
41 Chaher N, Arias-Pulido H, Terki N, Qualls C, Bouzid K, Verschraegen C, Wallace AM, Royce M. Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat 2012;131:437-44. [PMID: 21360074 DOI: 10.1007/s10549-011-1422-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
42 Kalinsky K, Hershman DL. Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting. J Comp Eff Res 2013;2:393-403. [PMID: 24236681 DOI: 10.2217/cer.13.35] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Preda M, Ilina R, Potre O, Potre C, Mazilu O. Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics. Cancer Manag Res 2020;12:12447-55. [PMID: 33299352 DOI: 10.2147/CMAR.S278795] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Shukla S, Jandzinski M, Wang C, Gong X, Bonk KW, Keri RA, Steinmetz NF. A Viral Nanoparticle Cancer Vaccine Delays Tumor Progression and Prolongs Survival in a HER2+ Tumor Mouse Model. Adv Ther (Weinh) 2019;2:1800139. [PMID: 33855164 DOI: 10.1002/adtp.201800139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
45 Kunnuru SKR, Thiyagarajan M, Martin Daniel J, Singh K B. A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma. Breast Cancer (Dove Med Press) 2020;12:259-66. [PMID: 33262647 DOI: 10.2147/BCTT.S277588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Hyder T, Bhattacharya S, Gade K, Nasrazadani A, Brufsky AM. Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. Breast Cancer (Dove Med Press) 2021;13:199-211. [PMID: 33833568 DOI: 10.2147/BCTT.S273058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Luangdilok S, Samarnthai N, Korphaisarn K. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. J Breast Cancer 2014;17:376-85. [PMID: 25548587 DOI: 10.4048/jbc.2014.17.4.376] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
48 Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 2012;30:2179-82. [PMID: 22614986 DOI: 10.1200/JCO.2012.42.0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
49 Pusch R. Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer. memo. [DOI: 10.1007/s12254-022-00819-4] [Reference Citation Analysis]
50 Alvarez RH, Hortobagyi GN. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer. Breast Cancer 2013;20:103-10. [PMID: 23377763 DOI: 10.1007/s12282-013-0446-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
51 Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, Jacobs I. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer 2018;119:266-73. [PMID: 30002437 DOI: 10.1038/s41416-018-0147-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
52 Zhang C, Guo Y, Li J, Tian X, Duan X. The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis. Medicine (Baltimore) 2019;98:e14261. [PMID: 30702584 DOI: 10.1097/MD.0000000000014261] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Bruno TC, French JD, Jordan KR, Ramirez O, Sippel TR, Borges VF, Haugen BR, McCarter MD, Waziri A, Slansky JE. Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res 2013;55:22-33. [PMID: 22941561 DOI: 10.1007/s12026-012-8346-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
54 Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014;3:e29030. [PMID: 25083328 DOI: 10.4161/onci.29030] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
55 Seal MD, Chia SK. Challenging the dogma on trastuzumab: a matter of the heart. The Lancet 2010;375:349-50. [DOI: 10.1016/s0140-6736(09)62069-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Hayashi M, Yamamoto Y, Takata N, Iwase H. A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character. Springerplus 2013;2:272. [PMID: 23875131 DOI: 10.1186/2193-1801-2-272] [Reference Citation Analysis]
57 Phung HT, Nguyen HT, Nguyen TV, Nguyen TV, Dinh LAT, Nguyen CV. Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam. Breast Cancer (Dove Med Press) 2020;12:117-22. [PMID: 33116813 DOI: 10.2147/BCTT.S268369] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Wong NS. Primary medical therapy and breast conservation treatment: the medical oncology perspective. Gland Surg 2018;7:560-75. [PMID: 30687629 DOI: 10.21037/gs.2018.10.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Bi Z, Qiu PF, Zhang Y, Song XG, Chen P, Xie L, Wang YS, Song XR. A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer. Front Oncol 2021;11:779140. [PMID: 34938660 DOI: 10.3389/fonc.2021.779140] [Reference Citation Analysis]
60 Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, Mukai H, Yasuda Y. Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett 2017;13:1731-40. [PMID: 28454317 DOI: 10.3892/ol.2017.5628] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
61 McGuire A, Kalinina O, Holian E, Curran C, Malone CA, McLaughlin R, Lowery A, Brown JAL, Kerin MJ. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab. Breast Cancer Res Treat 2017;164:221-9. [PMID: 28378298 DOI: 10.1007/s10549-017-4225-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
62 Cunquero-Tomás AJ, Ávila-Andrade CD, Milara J, Javier K, Iranzo V, Camps C. Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopausal woman: A case report and review of the literature. J Oncol Pharm Pract 2020;26:492-5. [PMID: 31260379 DOI: 10.1177/1078155219858173] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. Ann Surg Oncol 2016;23:1104-10. [PMID: 26511266 DOI: 10.1245/s10434-015-4934-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
64 Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. Breast Cancer (Dove Med Press) 2019;11:29-42. [PMID: 30643452 DOI: 10.2147/BCTT.S179750] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Advani P, Cornell L, Chumsri S, Moreno-Aspitia A. Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2015;7:321-35. [PMID: 26451122 DOI: 10.2147/BCTT.S90627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
66 Zhang S, Wang Y, Wang Y, Peng J, Yuan C, Zhou L, Xu S, Lin Y, Du Y, Yang F, Zhang J, Dai H, Yin W, Lu J. Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. Front Oncol 2020;10:631. [PMID: 32426280 DOI: 10.3389/fonc.2020.00631] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Fen H, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35238873 DOI: 10.1001/jamaoncol.2021.8171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. Br J Cancer 2016;114:44-52. [PMID: 26657653 DOI: 10.1038/bjc.2015.426] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
69 Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797-3803. [PMID: 21965336 DOI: 10.1172/jci57152] [Cited by in Crossref: 232] [Cited by in F6Publishing: 131] [Article Influence: 21.1] [Reference Citation Analysis]
70 Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, Lu J, Jin Y, Wei X, Zhang D. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 2014;14:823. [PMID: 25380654 DOI: 10.1186/1471-2407-14-823] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
71 Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers (Basel) 2021;13:4008. [PMID: 34439165 DOI: 10.3390/cancers13164008] [Reference Citation Analysis]
72 Milani A, Montemurro F, Gioeni L, Aglietta M, Valabrega G. Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press) 2010;2:93-109. [PMID: 24367170 DOI: 10.2147/BCTT.S6070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
73 Wecsler JS, Tereffe W, Pedersen RC, Sieffert MR, Mack WJ, Cui H, Russell CA, Woods RR, Viscusi RK, Sener SF, Lang JE. Lymph node status in inflammatory breast cancer. Breast Cancer Res Treat 2015;151:113-20. [PMID: 25846421 DOI: 10.1007/s10549-015-3367-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
74 Chen W, He J, Song S, Wang M, Wu H, Wang X. Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer. Oncol Lett 2015;9:1922-6. [PMID: 25789069 DOI: 10.3892/ol.2015.2912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
75 Williams SC. New yardstick could speed access to cancer drugs for surgery. Nat Med 2013;19:383. [PMID: 23558609 DOI: 10.1038/nm0413-383] [Reference Citation Analysis]
76 Bouwer NI, Jager A, Liesting C, Kofflard MJM, Brugts JJ, Kitzen JJEM, Boersma E, Levin MD. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. Breast 2020;52:33-44. [PMID: 32361151 DOI: 10.1016/j.breast.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Roth J, Simon N. A framework for estimating and testing qualitative interactions with applications to predictive biomarkers. Biostatistics 2018;19:263-80. [PMID: 28968765 DOI: 10.1093/biostatistics/kxx038] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Farnie G, Johnson RL, Williams KE, Clarke RB, Bundred NJ. Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS). Cell Cycle 2014;13:418-25. [PMID: 24247151 DOI: 10.4161/cc.27201] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
79 Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C. Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. Oncotarget 2018;9:27380-96. [PMID: 29937992 DOI: 10.18632/oncotarget.25270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
80 He X, Dai X, Ji J, Liu H, Shi G, Yeung SJ. Nine-Year Median Follow-up of Ccardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. Clin Breast Cancer 2021:S1526-8209(21)00136-1. [PMID: 34312098 DOI: 10.1016/j.clbc.2021.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
81 Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014;110:1139-1147. [PMID: 24457911 DOI: 10.1038/bjc.2013.831] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
82 Piwko C, Prady C, Yunger S, Pollex E, Moser A. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Clin Drug Investig 2015;35:487-93. [PMID: 26123628 DOI: 10.1007/s40261-015-0302-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
83 Nemeth BT, Varga ZV, Wu WJ, Pacher P. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol 2017;174:3727-48. [PMID: 27714776 DOI: 10.1111/bph.13643] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
84 Li ZW, Zhang M, Yang YJ, Zhou ZJ, Liu YL, Li H, Bao B, Diao JD, Wang DW. Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study. PeerJ 2020;8:e8512. [PMID: 32117621 DOI: 10.7717/peerj.8512] [Reference Citation Analysis]
85 Kolberg HC, Colleoni M, Santi P, Demetriou GS, Segui-Palmer MA, Fujiwara Y, Hurvitz SA, Hanes V. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Target Oncol 2019;14:647-56. [PMID: 31620980 DOI: 10.1007/s11523-019-00675-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
86 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
87 Conte B, Montemurro F, Levaggi A, Blondeaux E, Molinelli C, Cardinali B, Poggio F, Buzzatti G, Bighin C, Lambertini M, Del Mastro L. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. Tumori 2022;:3008916211067568. [PMID: 34989265 DOI: 10.1177/03008916211067568] [Reference Citation Analysis]
88 Nakhlis F, Portnow L, Gombos E, Daylan AEC, Leone JP, Kantor O, Richardson ET, Ho A, Dunn SA, Ohri N. Multidisciplinary Considerations in the Management of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Current Problems in Surgery 2022. [DOI: 10.1016/j.cpsurg.2022.101191] [Reference Citation Analysis]
89 Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg 2017;266:667-76. [PMID: 28657941 DOI: 10.1097/SLA.0000000000002373] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 6.2] [Reference Citation Analysis]
90 Mitri Z, Constantine T, O’Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012;2012:743193. [PMID: 23320171 DOI: 10.1155/2012/743193] [Cited by in Crossref: 108] [Cited by in F6Publishing: 150] [Article Influence: 10.8] [Reference Citation Analysis]
91 Makower D, Sparano JA. How do I treat inflammatory breast cancer? Curr Treat Options Oncol 2013;14:66-74. [PMID: 23160756 DOI: 10.1007/s11864-012-0214-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
92 Abdel-Razeq H, Mansour A, Jaddan D. Breast Cancer Care in Jordan. JCO Glob Oncol 2020;6:260-8. [PMID: 32083950 DOI: 10.1200/JGO.19.00279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
93 Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol 2015;38:242-7. [PMID: 23648437 DOI: 10.1097/COC.0b013e3182937921] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
94 Mamounas E, Poulos C, Goertz HP, González JM, Pugh A, Antao V. Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. Ann Surg Oncol 2016;23:3510-7. [PMID: 27283292 DOI: 10.1245/s10434-016-5296-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
95 Hung C, Tsai I, Hsu C, Lin H. Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study. JCM 2022;11:1434. [DOI: 10.3390/jcm11051434] [Reference Citation Analysis]
96 Jaques R, Xu S, Matsakas A. Evaluating Trastuzumab in the treatment of HER2 positive breast cancer. Histol Histopathol 2020;35:1059-75. [PMID: 32323293 DOI: 10.14670/HH-18-221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, Perez-Montero H, Fernandez-Montolí E, Stradella A, Recalde S, Soler T, Petit A, Bajen MT, Benitez A, Guma A, Campos M, Pla MJ, Martinez E, Laplana M, Pernas S, Perez-Sildekova D, Catala I, Ponce J, Falo C. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC? Breast Cancer Res Treat 2021;185:657-66. [PMID: 33068198 DOI: 10.1007/s10549-020-05970-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Shah S, Chen B. Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int 2010;2011:903202. [PMID: 21188214 DOI: 10.4061/2011/903202] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
99 Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer 2014;14:326. [PMID: 24885187 DOI: 10.1186/1471-2407-14-326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
100 Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol 2015;22:1408-15. [PMID: 25727557 DOI: 10.1245/s10434-015-4405-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
101 Sun GY, Jing H, Wang SL, Song YW, Jin J, Fang H, Liu YP, Ren H, Tang Y, Zhao XR, Song YC, Chen SY, Yang ZB, Chen B, Tang Y, Li N, Lu NN, Qi SN, Yang Y, Li YX. Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy. Front Oncol 2020;10:605750. [PMID: 33575216 DOI: 10.3389/fonc.2020.605750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Gonda K, Watanabe M, Tada H, Miyashita M, Takahashi-Aoyama Y, Kamei T, Ishida T, Usami S, Hirakawa H, Kakugawa Y, Hamanaka Y, Yoshida R, Furuta A, Okada H, Goda H, Negishi H, Takanashi K, Takahashi M, Ozaki Y, Yoshihara Y, Nakano Y, Ohuchi N. Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness. Sci Rep 2017;7:7509. [PMID: 28790306 DOI: 10.1038/s41598-017-06534-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
103 Yoshida A, Hayashi N. Reply to Kadri Altundag. J Surg Oncol 2018;117:329. [PMID: 28968921 DOI: 10.1002/jso.24838] [Reference Citation Analysis]
104 Moya-Horno I, Cortés J. The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2015;7:125-32. [PMID: 26056489 DOI: 10.2147/BCTT.S61579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
105 Pu S, Wang K, Liu Y, Liao X, Chen H, He J, Zhang J. Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT). BMC Cancer 2020;20:1120. [PMID: 33213397 DOI: 10.1186/s12885-020-07621-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
106 Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer 2017;116:509-14. [PMID: 28081544 DOI: 10.1038/bjc.2016.444] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
107 Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer 2015;22:586-95. [PMID: 24574277 DOI: 10.1007/s12282-014-0524-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
108 Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S. Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open 2018;3:e000381. [PMID: 30018811 DOI: 10.1136/esmoopen-2018-000381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
109 Rossi D, Pistilli B, Morale D, Baldelli, Casadei V, Benedetti G, Alessandroni P, Catalano V, Giordani P, Graziano F, Fedeli SL, Fiorentini G. "Short Course" of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07). World J Oncol 2011;2:245-51. [PMID: 29147255 DOI: 10.4021/wjon393w] [Reference Citation Analysis]
110 Qu F, Li Z, Lai S, Zhong X, Fu X, Huang X, Li Q, Liu S, Li H. Construction and Validation of a Serum Albumin-to-Alkaline Phosphatase Ratio-Based Nomogram for Predicting Pathological Complete Response in Breast Cancer. Front Oncol 2021;11:681905. [PMID: 34692474 DOI: 10.3389/fonc.2021.681905] [Reference Citation Analysis]
111 Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, Ahn SH, Son BH, Gong G. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer 2012;15:203-10. [PMID: 22807938 DOI: 10.4048/jbc.2012.15.2.203] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
112 Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, Extra JM, Tallet A, Lambaudie E, Jacquemier J, Houvenaeghel G, Boher JM, Viens P, Bertucci F. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget 2017;8:66019-32. [PMID: 29029489 DOI: 10.18632/oncotarget.19732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
113 Futamura M, Oba M, Masuda N, Bando H, Okada M, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Ohno S. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer 2021;28:1023-37. [PMID: 33811599 DOI: 10.1007/s12282-021-01238-9] [Reference Citation Analysis]
114 Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Tamirisa N, Force J, Boughey JC, Hyslop T, Hwang ES. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). Ann Surg 2018;268:591-601. [PMID: 30048319 DOI: 10.1097/SLA.0000000000002953] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
115 Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1317-1325. [PMID: 24239210 DOI: 10.1016/s1470-2045(13)70502-3] [Cited by in Crossref: 109] [Cited by in F6Publishing: 53] [Article Influence: 12.1] [Reference Citation Analysis]
116 Krishnan Y, Al Awadi S, Sreedharan PS, Sujith Nair S, Thuruthel S. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait. Asia Pac J Clin Oncol 2016;12:e30-7. [PMID: 23937427 DOI: 10.1111/ajco.12118] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O'Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Am J Clin Pathol 2016;145:871-8. [PMID: 27298399 DOI: 10.1093/ajcp/aqw045] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
118 Pathak M, Dwivedi SN, Deo SVS, Thakur B, Sreenivas V, Rath GK. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev 2018;7:89. [PMID: 29945652 DOI: 10.1186/s13643-018-0754-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
119 Zhang J, Yu Y, Lin Y, Kang S, Lv X, Liu Y, Lin J, Wang J, Song C. Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. Ther Adv Med Oncol 2021;13:17588359211006948. [PMID: 33868462 DOI: 10.1177/17588359211006948] [Reference Citation Analysis]
120 Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS One 2015;10:e0129876. [PMID: 26075403 DOI: 10.1371/journal.pone.0129876] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
121 Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc 2017;6:e006915. [PMID: 28939718 DOI: 10.1161/JAHA.117.006915] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
122 Boér K, Kahán Z, Landherr L, Csőszi T, Máhr K, Ruzsa Á, Horváth Z, Budai B, Rubovszky G. Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience. Pathol Oncol Res 2021;27:1609785. [PMID: 34257621 DOI: 10.3389/pore.2021.1609785] [Reference Citation Analysis]
123 Hoover S, Bloom E, Patel S. Review of breast conservation therapy: then and now. ISRN Oncol 2011;2011:617593. [PMID: 22229101 DOI: 10.5402/2011/617593] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
124 Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015;16:1037-48. [PMID: 26272770 DOI: 10.1016/S1470-2045(15)00041-8] [Cited by in Crossref: 99] [Cited by in F6Publishing: 48] [Article Influence: 14.1] [Reference Citation Analysis]
125 Won HS, Kim YS, Kim JS, Chang ED, Na SJ, Whang IY, Lee DS. Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer. Korean J Intern Med 2020;35:1489-96. [PMID: 32069523 DOI: 10.3904/kjim.2019.031] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer 2018;25:407-15. [PMID: 29445928 DOI: 10.1007/s12282-018-0839-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
127 Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E, Pernas S, Prat A, Servitja S, Ciruelos E. SEOM clinical guidelines in early stage breast cancer (2018). Clin Transl Oncol 2019;21:18-30. [PMID: 30443868 DOI: 10.1007/s12094-018-1973-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
128 Garcia-Saenz JA, Bermejo B, Estevez LG, Palomo AG, Gonzalez-Farre X, Margeli M, Pernas S, Servitja S, Rodriguez CA, Ciruelos E. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol 2015;17:939-45. [PMID: 26497356 DOI: 10.1007/s12094-015-1427-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
129 Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat 2013;137:523-31. [PMID: 23184079 DOI: 10.1007/s10549-012-2336-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
130 Zhang M, Li L, Zhang S, Zhu W, Yang S, Di G, Ma X, Yang H. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study. Biomed Res Int 2020;2020:3208391. [PMID: 32461977 DOI: 10.1155/2020/3208391] [Reference Citation Analysis]
131 Gu X, Jia S, Wei W, Zhang WH. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel. Tumour Biol 2015;36:5529-35. [PMID: 25682286 DOI: 10.1007/s13277-015-3221-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
132 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
133 Addetia K, Decara JM. Cardiac Complications of HER2-Targeted Therapies in Breast Cancer. Curr Treat Options Cardio Med 2016;18. [DOI: 10.1007/s11936-016-0458-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Crocamo S, Binato R, de Paula B, Vignal G, Magalhães L, Sarmento R, Accioly MT, Small I, Gioia S, Maroun P, Moutinho P, Freitas V, Catein K, Abdelhay E. Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. Ther Adv Med Oncol 2019;11:1758835919853971. [PMID: 31210800 DOI: 10.1177/1758835919853971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
135 Jagosky M, Tan AR. Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast Cancer (Dove Med Press) 2021;13:393-407. [PMID: 34163239 DOI: 10.2147/BCTT.S176514] [Reference Citation Analysis]
136 Moulder SL. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clin Breast Cancer 2010;10 Suppl 2:S30-40. [PMID: 20805063 DOI: 10.3816/CBC.2010.s.010] [Reference Citation Analysis]
137 Ribeiro J, Sousa B, Cardoso F. Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl 2013;11:3-22. [PMID: 26217109 DOI: 10.1016/j.ejcsup.2013.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
138 Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol 2015;12:147-62. [PMID: 25668732 DOI: 10.1038/nrclinonc.2015.13] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 8.6] [Reference Citation Analysis]
139 Goldvaser H, Korzets Y, Shepshelovich D, Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P, Amir E. Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectr 2019;3:pkz033. [PMID: 31360906 DOI: 10.1093/jncics/pkz033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
140 Futamura M, Nagao Y, Ishihara K, Takeuchi M, Nakada T, Kawaguchi Y, Asano M, Kumazawa I, Shiroko T, Morimitsu K, Mori R, Nawa M, Shimokawa T, Yoshida K. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial. Breast Cancer 2017;24:615-23. [PMID: 28050738 DOI: 10.1007/s12282-016-0748-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
141 Abdel-Razeq H, Marei L. Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 2011;5:87-94. [PMID: 21847344 DOI: 10.2147/BTT.S22917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
142 Wu Q, Bai B, Tian C, Li D, Yu H, Song B, Li B, Chu X. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. Cardiovasc Drugs Ther 2021. [PMID: 33847848 DOI: 10.1007/s10557-021-07181-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol 2014;4:346. [PMID: 25538891 DOI: 10.3389/fonc.2014.00346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
144 Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H. Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series. Breast Cancer (Dove Med Press) 2015;7:245-50. [PMID: 26357489 DOI: 10.2147/BCTT.S90975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23 Suppl 10:x231-x236. [PMID: 22987968 DOI: 10.1093/annonc/mds324] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 12.3] [Reference Citation Analysis]
146 Hu H, Steinmetz NF. Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine. Cancers (Basel) 2021;13:2909. [PMID: 34200802 DOI: 10.3390/cancers13122909] [Reference Citation Analysis]
147 Guiu S, Mouret Reynier MA, Toure M, Coudert B. Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. J Oncol. 2013;2013:854121. [PMID: 23737784 DOI: 10.1155/2013/854121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
148 Liu X, Mai J, Meng C, Spiegel AJ, Wei W, Shen H. Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine. IJN 2022;Volume 17:203-12. [DOI: 10.2147/ijn.s341394] [Reference Citation Analysis]
149 Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC. Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. Proc Natl Acad Sci U S A 2018;115:E2594-603. [PMID: 29476008 DOI: 10.1073/pnas.1717820115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
150 Yu T, Cho BJ, Choi EJ, Park JM, Kim DH, Kim IA. Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells. Oncotarget 2016;7:79089-100. [PMID: 27738326 DOI: 10.18632/oncotarget.12597] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
151 Zhao B, Zhao Y, Sun Y, Niu H, Sheng L, Huang D, Li L. Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer. Mol Med Rep 2018;18:139-46. [PMID: 29750305 DOI: 10.3892/mmr.2018.8981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M, Gonçalves A. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Front Oncol 2020;10:575978. [PMID: 33330051 DOI: 10.3389/fonc.2020.575978] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
153 Nanou A, Zeune LL, Bidard FC, Pierga JY, Terstappen LWMM. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. Breast Cancer Res 2020;22:86. [PMID: 32787900 DOI: 10.1186/s13058-020-01323-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
154 Ding J, Yang Y, Jiang L, Wu W, Shao Z. Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab. Oncotarget 2017;8:56626-34. [PMID: 28915617 DOI: 10.18632/oncotarget.17993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
155 Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget 2016;7:13209-20. [PMID: 26334099 DOI: 10.18632/oncotarget.4801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
156 De Silva N, Schulz L, Paterson A, Qain W, Secrier M, Godfrey E, Cheow H, O'Donovan M, Lao-Sirieix P, Jobanputra M, Hochhauser D, Fitzgerald R, Ford H. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer 2015;113:1305-12. [PMID: 26484410 DOI: 10.1038/bjc.2015.342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
157 Li AC, Zhao J, Zhao C, Ma Z, Hartage R, Zhang Y, Li X, Parwani AV. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat 2020;180:321-9. [PMID: 32002765 DOI: 10.1007/s10549-020-05546-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
158 Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129. [PMID: 23025714 DOI: 10.1186/bcr3324] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 7.8] [Reference Citation Analysis]
159 Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Viel E, Comaro E, Talamini R, Bidoli E, Turchet E, Crivellari D, Dolcetti R. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer 2014;14:954. [PMID: 25512030 DOI: 10.1186/1471-2407-14-954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
160 Munagala R, Aqil F, Gupta RC. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 2011;43:236-45. [PMID: 21713084 DOI: 10.4103/0253-7613.81497] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
161 Cao R, Chen J, Zhang X, Zhai Y, Qing X, Xing W, Zhang L, Malik YS, Yu H, Zhu X. Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis. Br J Cancer 2014;111:539-50. [PMID: 24921915 DOI: 10.1038/bjc.2014.298] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
162 Lønning PE. Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol 2012;4:127-37. [PMID: 22590486 DOI: 10.1177/1758834012439338] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
163 Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016;8:429-49. [PMID: 27800032 DOI: 10.1177/1758834016665077] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
164 Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Medicine (Baltimore) 2018;97:e11647. [PMID: 30045313 DOI: 10.1097/MD.0000000000011647] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
165 Li S, Wei W, Jiang Y, Li Q, Huang Q, Yang H, Liu J. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. Drug Des Devel Ther 2018;12:3085-93. [PMID: 30275685 DOI: 10.2147/DDDT.S171534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
166 Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420-8. [PMID: 28961844 DOI: 10.1093/annonc/mdx397] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
167 Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. J Cancer Res Clin Oncol 2013;139:1229-40. [PMID: 23604446 DOI: 10.1007/s00432-013-1436-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
168 Thomas M, Poignée-Heger M, Weisser M, Wessner S, Belousov A. An optimized workflow for improved gene expression profiling for formalin-fixed, paraffin-embedded tumor samples. J Clin Bioinforma 2013;3:10. [PMID: 23641797 DOI: 10.1186/2043-9113-3-10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
169 Gunia SR, Patel MS, Mamounas EP. Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature. Case Rep Surg 2012;2012:454273. [PMID: 22606601 DOI: 10.1155/2012/454273] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
170 Hong J, Park YH. Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. Ther Adv Med Oncol 2022;14:17588359221106564. [PMID: 35756967 DOI: 10.1177/17588359221106564] [Reference Citation Analysis]
171 Arias-Pulido H, Cimino-Mathews AM, Chaher N, Qualls CR, Joste N, Colpaert C, Marotti JD, Chamberlin MD, Foisey MG, Prossnitz ER, Emens LA, Fiering S. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients. Breast Cancer Res Treat 2021;190:477-89. [PMID: 34542773 DOI: 10.1007/s10549-021-06391-5] [Reference Citation Analysis]
172 Park YH, Lal S, Lee JE, Choi YL, Wen J, Ram S, Ding Y, Lee SH, Powell E, Lee SK, Yu JH, Ching KA, Nam JY, Kim SW, Nam SJ, Kim JY, Cho SY, Park S, Kim J, Hwang S, Kim YJ, Bonato V, Fernandez D, Deng S, Wang S, Shin H, Kang ES, Park WY, Rejto PA, Bienkowska J, Kan Z. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun 2020;11:6175. [PMID: 33268821 DOI: 10.1038/s41467-020-19933-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
173 Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014;19:135-50. [PMID: 24436312 DOI: 10.1634/theoncologist.2013-0283] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
174 Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016;2:929-936. [PMID: 26986538 DOI: 10.1001/jamaoncol.2015.6478] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 12.4] [Reference Citation Analysis]
175 Li JW, Mo M, Yu KD, Chen CM, Hu Z, Hou YF, Di GH, Wu J, Shen ZZ, Shao ZM, Liu GY. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. PLoS One 2014;9:e114646. [PMID: 25504233 DOI: 10.1371/journal.pone.0114646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
176 Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A, Enrici RM. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011;6:48. [PMID: 21575163 DOI: 10.1186/1748-717X-6-48] [Cited by in Crossref: 366] [Cited by in F6Publishing: 169] [Article Influence: 33.3] [Reference Citation Analysis]
177 Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Huober J, Romagnoli D, Boccalini G, Vitale S, Sotiriou C, Biganzoli L, Di Leo A, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol 2019;11:1758835919891608. [PMID: 31853266 DOI: 10.1177/1758835919891608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Uriarte-Pinto M, Escolano-Pueyo Á, Gimeno-Ballester V, Pascual-Martínez O, Abad-Sazatornil MR, Agustín-Ferrández MJ. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer. Int J Clin Pharm 2016;38:446-53. [PMID: 26951122 DOI: 10.1007/s11096-016-0278-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
179 Floros KV, Jacob S, Kurupi R, Fairchild CK, Hu B, Puchalapalli M, E Koblinski J, Dozmorov MG, Boikos SA, Scaltriti M, Faber AC. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell Death Dis 2021;12:179. [PMID: 33589591 DOI: 10.1038/s41419-021-03457-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
180 Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG. Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol 2018;12:1838-55. [PMID: 30133130 DOI: 10.1002/1878-0261.12375] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
181 Graffagnino J, Kondapalli L, Arora G, Hawi R, Lenneman CG. Strategies to Prevent Cardiotoxicity. Curr Treat Options Oncol 2020;21:32. [PMID: 32270293 DOI: 10.1007/s11864-020-0722-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
182 Saqafi B, Rahbarizadeh F. Specific targeting of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer cells by polyethylene glycol-grafted polyethyleneimine modified with anti-HER2 single-domain antibody. Journal of Bioactive and Compatible Polymers 2018;33:17-37. [DOI: 10.1177/0883911517707775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
183 Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res 2018;20:27. [PMID: 29661243 DOI: 10.1186/s13058-018-0945-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
184 Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 2014;5:154-66. [PMID: 25083270 DOI: 10.1177/2042098614529603] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
185 Ricciardi GR, Franchina T, Russo A, Schifano S, Ferraro G, Adamo V. Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer. Onco Targets Ther 2016;9:4351-5. [PMID: 27499629 DOI: 10.2147/OTT.S107930] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
186 Hu X, Li T, Wang B, Zhang J, Yu X, Shao Z. Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline. Breast 2019;45:36-42. [PMID: 30826525 DOI: 10.1016/j.breast.2019.02.009] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
187 Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res 2015;17:71. [PMID: 25997452 DOI: 10.1186/s13058-015-0584-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
188 Di Cosimo S. Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol 2011;6:189-95. [PMID: 22125051 DOI: 10.1007/s11523-011-0203-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
189 Arranz EE, Vara JÁ, Gámez-Pozo A, Zamora P. Gene signatures in breast cancer: current and future uses. Transl Oncol 2012;5:398-403. [PMID: 23323153 DOI: 10.1593/tlo.12244] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
190 Gampenrieder SP, Rinnerthaler G, Greil R. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol 2013;2013:732047. [PMID: 24027583 DOI: 10.1155/2013/732047] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
191 De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119:1776-1783. [PMID: 23436342 DOI: 10.1002/cncr.27995] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 13.3] [Reference Citation Analysis]
192 Gavilá J, Guerrero Á, Climent MÁ, Fernández A, Gozalbo F, Carrascosa M, Camps J, Guillem V, Ruiz A. Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice. Int J Clin Oncol 2015;20:480-9. [PMID: 25011497 DOI: 10.1007/s10147-014-0727-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
193 Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am 2014;23:505-23. [PMID: 24882348 DOI: 10.1016/j.soc.2014.03.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
194 Altoe ML, Kalinsky K, Marone A, Kim HK, Guo H, Hibshoosh H, Tejada M, Crew KD, Accordino MK, Trivedi MS, Hershman DL, Hielscher AH. Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. Clin Cancer Res 2021;27:1949-57. [PMID: 33451976 DOI: 10.1158/1078-0432.CCR-20-1108] [Reference Citation Analysis]
195 Xu ZQ, Zhang Y, Li N, Liu PJ, Gao L, Gao X, Tie XJ. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017;7:e013053. [PMID: 28289045 DOI: 10.1136/bmjopen-2016-013053] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
196 Zhou J, Lei J, Wang J, Lian CL, Hua L, Yang LC, Wu SG. Validation of the 8th edition of the American Joint Committee on Cancer Pathological Prognostic Staging for young breast cancer patients. Aging (Albany NY) 2020;12:7549-60. [PMID: 32320950 DOI: 10.18632/aging.103111] [Reference Citation Analysis]
197 Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst 2014;106:dju152. [PMID: 25139534 DOI: 10.1093/jnci/dju152] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 13.4] [Reference Citation Analysis]
198 Criscitiello C, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ. Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res 2012;14:209. [PMID: 22713170 DOI: 10.1186/bcr3142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
199 Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open 2022;7:100433. [PMID: 35276440 DOI: 10.1016/j.esmoop.2022.100433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
200 Boudin L, Gonçalves A, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Chabannon C. Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. J Cancer 2016;7:2077-84. [PMID: 27877223 DOI: 10.7150/jca.15797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 2015;26:325-32. [PMID: 25467016 DOI: 10.1093/annonc/mdu551] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
202 Sethjiwala T, Dhanushkodi M, Radhakrishnan V, Kalaiarasi JP, Mehra N, Joshi A, Rajan AK, Selvarajan G, Ananthi B, Iyer P, Senguttuvan G, Srilatha B, Ranganathan R, Sundersingh S, Krishnamurthy A, Velusamy S, Raj H, Ganesarajah S, Sagar TG, Ganesan TS. Adjuvant Short-Course Trastuzumab in Breast Cancer. Indian J Gynecol Oncolog 2019;17. [DOI: 10.1007/s40944-019-0313-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
203 Ma X, Wang X, Huang J, Chen Y, Zhang J, Zhang B, Shi C, Liu L. Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. PLoS One 2016;11:e0160148. [PMID: 27579484 DOI: 10.1371/journal.pone.0160148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
204 Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 2015;68:93-9. [PMID: 25488926 DOI: 10.1136/jclinpath-2014-202571] [Cited by in Crossref: 137] [Cited by in F6Publishing: 125] [Article Influence: 17.1] [Reference Citation Analysis]
205 Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486. [PMID: 22081974 DOI: 10.1186/1471-2407-11-486] [Cited by in Crossref: 161] [Cited by in F6Publishing: 176] [Article Influence: 14.6] [Reference Citation Analysis]
206 Zhang X, Wang D, Liu Z, Wang Z, Li Q, Xu H, Zhang B, Liu T, Jin F. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. Quant Imaging Med Surg 2020;10:197-210. [PMID: 31956542 DOI: 10.21037/qims.2019.11.16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
207 López C, Tomás B, Korzynska A, Bosch R, Salvadó MT, Llobera M, Garcia-Rojo M, Alvaro T, Jaén J, Lejeune M. Is it necessary to evaluate nuclei in HER2 FISH evaluation? Am J Clin Pathol 2013;139:47-54. [PMID: 23270898 DOI: 10.1309/AJCPPXLYJVFGOV8I] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Chica-Parrado MR, Godoy-Ortiz A, Jiménez B, Ribelles N, Barragan I, Alba E. Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers (Basel) 2020;12:E2012. [PMID: 32708049 DOI: 10.3390/cancers12082012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Huang Q, Xu TY, Wu ZY. Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study. Med Sci Monit 2019;25:9167-78. [PMID: 31789307 DOI: 10.12659/MSM.919458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
210 Kang I, Dong S, Lu J, Xia B. Recent Developments in HER2-Directed Therapy in Breast Cancer. Curr Breast Cancer Rep 2019;11:311-25. [DOI: 10.1007/s12609-019-00347-x] [Reference Citation Analysis]
211 Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. [DOI: 10.1136/bmj-2021-066381] [Reference Citation Analysis]
212 Li Y, Zhang R, Han Y, Lu T, Ding J, Zhang K, Lin G, Xie J, Li J. Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection. Diagn Pathol 2016;11:85. [PMID: 27613595 DOI: 10.1186/s13000-016-0537-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
213 Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1-12. [PMID: 23563986 DOI: 10.1007/s10120-013-0252-z] [Cited by in Crossref: 158] [Cited by in F6Publishing: 150] [Article Influence: 17.6] [Reference Citation Analysis]
214 Pernas Simon S. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications. Ther Adv Med Oncol 2014;6:210-21. [PMID: 25342988 DOI: 10.1177/1758834014535650] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
215 Wu D, Chen T, Jiang H, Duan C, Zhang X, Lin Y, Chen S, Wu F. Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis. J Oncol 2019;2019:3406972. [PMID: 31015833 DOI: 10.1155/2019/3406972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
216 Huszno J, Nowara E. Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients. Contemp Oncol (Pozn) 2016;20:1-7. [PMID: 27095932 DOI: 10.5114/wo.2016.58495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
217 Candon D, Healy J, Crown J. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. Acta Oncol 2014;53:201-8. [PMID: 24125103 DOI: 10.3109/0284186X.2013.840740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Hall BJ, Bhojwani AA, Wong H, Law A, Flint H, Ahmed E, Innes H, Cliff J, Malik Z, O’hagan JE, Hall A, Sripadam R, Tolan S, Ali Z, Hart C, Errington D, Alam F, Giuliani R, Mehta S, Khanduri S, Thorp N, Jackson R, Cicconi S, Palmieri C, Mishra A. Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. The Breast Journal 2022;2022:1-10. [DOI: 10.1155/2022/7146172] [Reference Citation Analysis]
219 Palshof FK, Lanng C, Kroman N, Benian C, Vejborg I, Bak A, Talman ML, Balslev E, Tvedskov TF. Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting. Ann Surg Oncol 2021. [PMID: 34043094 DOI: 10.1245/s10434-021-10117-8] [Reference Citation Analysis]
220 Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer (Auckl) 2020;14:1178223420980377. [PMID: 33402827 DOI: 10.1177/1178223420980377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
221 Shen S, Xu Y, Zhou Y, Mao F, Guan J, Sun Q. Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial. Oncotarget 2017;8:92778-87. [PMID: 29190955 DOI: 10.18632/oncotarget.21579] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Ding Y, Ding K, Yang H, He X, Mo W, Ding X. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients. PLoS One 2020;15:e0234058. [PMID: 32470093 DOI: 10.1371/journal.pone.0234058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
223 Abramson VG, Mayer IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol 2012;4:139-47. [PMID: 22590487 DOI: 10.1177/1758834012440834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
224 Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M, Prat A. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. Front Oncol 2019;9:707. [PMID: 31448227 DOI: 10.3389/fonc.2019.00707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
225 Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, Dimopoulos MA. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer 2014;14:515. [PMID: 25026897 DOI: 10.1186/1471-2407-14-515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
226 Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol 2014;53:1440-5. [PMID: 24991893 DOI: 10.3109/0284186X.2014.921727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
227 Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget 2018;9:35687-704. [PMID: 30479698 DOI: 10.18632/oncotarget.26286] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
228 Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers (Basel) 2020;12:E2479. [PMID: 32883032 DOI: 10.3390/cancers12092479] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
229 Han A, Lee KE, Lee HK, Park YH, Kim J, Kim SW, Jung KH, Son BH; Korean Breast Cancer Treatment Consensus Conference Panelists. Meeting highlights: the first korean breast cancer treatment consensus conference. J Breast Cancer 2014;17:308-13. [PMID: 25548577 DOI: 10.4048/jbc.2014.17.4.308] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Jahani N, Cohen E, Hsieh MK, Weinstein SP, Pantalone L, Hylton N, Newitt D, Davatzikos C, Kontos D. Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. Sci Rep 2019;9:12114. [PMID: 31431633 DOI: 10.1038/s41598-019-48465-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
231 Yu KD, Liu GY, Chen CM, Li JW, Wu J, Lu JS, Shen ZZ, Shao ZM. Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule. Oncologist 2013;18:511-7. [PMID: 23635560 DOI: 10.1634/theoncologist.2012-0057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
232 Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A. Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. J Clin Med 2019;8:E612. [PMID: 31064127 DOI: 10.3390/jcm8050612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
233 Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, Prat A. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. BMC Med 2019;17:8. [PMID: 30621698 DOI: 10.1186/s12916-018-1233-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
234 Özdemir Ö, Zengel B, Yildiz Y, Oyan Uluç B, Çabuk D, Özden E, Kivrak Salim D, Paydas S, Demir A, Diker Ö, Nur Pilanci K, Uysal Sönmez Ö, Vatansever S, Doğan İ, Gülmez A, Çakar B, Gürsoy P, Emre Yildirim M, Ayhan M, Karadurmuş N, Bariş Aykan M, Tuğba Çevik G, Şakalar T, Hacibekiroğlu İ, Belen Gülbağci B, Dinçer M, Bayir Garbioğlu D, Kemal Y, Nayir E, Taşkaynatan H, Yilmaz M, Avci O, Sari M, Çoban E, Mustafa Atci M, Aktürk Esen S, Akin Telli T, Karataş F, İnal A, Demir H, Önal Kalkan N, Yilmaz C, Taşli F, Alacacioğlu A. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs 2022. [PMID: 35703239 DOI: 10.1097/CAD.0000000000001310] [Reference Citation Analysis]
235 Noblejas-López MDM, Nieto-Jiménez C, Galán-Moya EM, Tebar-García D, Montero JC, Pandiella A, Burgos M, Ocaña A. MZ1 co-operates with trastuzumab in HER2 positive breast cancer. J Exp Clin Cancer Res 2021;40:106. [PMID: 33741018 DOI: 10.1186/s13046-021-01907-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Di Modica M, Tagliabue E, Triulzi T. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. Dis Markers 2017;2017:7849108. [PMID: 29403144 DOI: 10.1155/2017/7849108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
237 Pernaut C, Lopez F, Ciruelos E. Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer. Breast Care (Basel) 2018;13:244-9. [PMID: 30319326 DOI: 10.1159/000491759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
238 Bae SJ, Kim JH, Ahn SG, Jeung HC, Sohn J, Kim GM, Kim MH, Kim SI, Park S, Park HS, Kim JY, Jeong J. Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. Front Oncol 2021;11:689587. [PMID: 34150658 DOI: 10.3389/fonc.2021.689587] [Reference Citation Analysis]
239 Papadimitriou K, Ardavanis A, Kountourakis P. Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium. J Thorac Dis 2010;2:160-70. [PMID: 22263038 DOI: 10.3978/j.issn.2072-1439.2010.02.03.8] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
240 Ismaili N, Elyaakoubi H, Bensouda Y, Errihani H. Demographic, clinical, pathological, molecular, treatment characteristics and outcomes of nonmetastatic inflammatory breast cancer in Morocco: 2007 and 2008. Exp Hematol Oncol 2014;3:1. [PMID: 24387242 DOI: 10.1186/2162-3619-3-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
241 González-Santiago S, Saura C, Ciruelos E, Alonso JL, de la Morena P, Santisteban Eslava M, Gallegos Sancho MI, de Luna A, Dalmau E, Servitja S, Ruiz Borrego M, Chacón JI. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Res Treat 2020;184:469-79. [PMID: 32876911 DOI: 10.1007/s10549-020-05866-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
242 Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone vs chemotherapy plus trastuzumab, vs chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019;19:494. [PMID: 31126258 DOI: 10.1186/s12885-019-5675-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
243 Qiu MZ, Shi SM, Chen M, Wang J, Wu QN, Sheng H, Zhang HZ, Yun JP, Zhou ZW, Wang FH, Yang DJ, Xu RH. Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer. J Cancer 2017;8:3531-7. [PMID: 29151938 DOI: 10.7150/jca.19984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
244 Wu J, Liu H, Hu T, Wang S. Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. Hereditas 2022;159:18. [PMID: 35317849 DOI: 10.1186/s41065-022-00230-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Chen YY, Wang LW, Chen FF, Wu BB, Xiong B. Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis. Exp Ther Med 2016;11:1721-33. [PMID: 27168794 DOI: 10.3892/etm.2016.3095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
246 Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-640. [PMID: 22257673 DOI: 10.1016/s0140-6736(11)61847-3] [Cited by in Crossref: 853] [Cited by in F6Publishing: 386] [Article Influence: 85.3] [Reference Citation Analysis]
247 Cai JH, Zheng JH, Lin XQ, Lin WX, Zou J, Chen YK, Li ZY, Chen YX. Individualized treatment of breast cancer with chronic renal failure: A case report and review of literature. World J Clin Cases 2021; 9(33): 10345-10354 [PMID: 34904109 DOI: 10.12998/wjcc.v9.i33.10345] [Reference Citation Analysis]
248 Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243. [PMID: 22513938 DOI: 10.1002/14651858.cd006243.pub2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 165] [Article Influence: 11.3] [Reference Citation Analysis]
249 O'Leary MP, Beckord BJ, Mock KE, Venegas RJ, Yeh JJ, Dauphine CE, Ozao-Choy JJ. A new era of neoadjuvant treatment with Pertuzumab: Should the 10-lymph node guideline for axillary lymph node dissection in breast cancer be revised? Cancer Rep (Hoboken) 2018;1:e1132. [PMID: 32729253 DOI: 10.1002/cnr2.1132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Krisam J, Kieser M. Optimal Interim Decision Rules Based on a Binary Surrogate Outcome for Adaptive Biomarker-Based Trials in Oncology. Statistics in Biopharmaceutical Research 2017;9:321-32. [DOI: 10.1080/19466315.2017.1323670] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
251 Silva LCFF, Arruda LSM, David Filho WJ, Cruz FJSM, Trufelli DC, Del Giglio A. Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer. Einstein (Sao Paulo) 2019;17:eAO3434. [PMID: 30673053 DOI: 10.31744/einstein_journal/2019AO3434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
252 Xu B, Hu X, Zheng H, Wang X, Zhang Q, Cui S, Liu D, Liao N, Luo R, Sun Q, Yu S. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. Oncotarget 2016;7:50643-55. [PMID: 27276706 DOI: 10.18632/oncotarget.9331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
253 Ueno NT, Mamounas EP. Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 2016;156:427-40. [PMID: 27072366 DOI: 10.1007/s10549-016-3778-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
254 Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 2016;21:21-7. [PMID: 26659222 DOI: 10.1634/theoncologist.2015-0101] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
255 Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, Mann RM, van Ramshorst MS, Lips EH, Vrancken Peeters MTFD, van Duijnhoven FH, Wesseling J. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Res Treat 2021;189:213-24. [PMID: 33945043 DOI: 10.1007/s10549-021-06235-2] [Reference Citation Analysis]
256 Ferreira AR, Saini KS, Metzger-Filho O. Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience 2015;9:523. [PMID: 25932047 DOI: 10.3332/ecancer.2015.523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
257 Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 2010;124:723-32. [PMID: 20878462 DOI: 10.1007/s10549-010-1181-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
258 Davari M, Amani B, Mokarian F, Hoseini M, Akbarzadeh A, Heidarzadeh Khoramabadi N. Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis. Med J Islam Repub Iran 2017;31:88. [PMID: 29951389 DOI: 10.14196/mjiri.31.88] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
259 Zong Y, Wu J, Shen K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget 2017;8:17360-72. [PMID: 28061451 DOI: 10.18632/oncotarget.14477] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
260 Ban M, Petrić Miše B, Vrdoljak E. Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches. Breast Care (Basel) 2020;15:560-9. [PMID: 33447229 DOI: 10.1159/000511883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014;23:128-36. [PMID: 24360619 DOI: 10.1016/j.breast.2013.11.011] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 12.6] [Reference Citation Analysis]
262 Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012;118:2385-93. [PMID: 21953213 DOI: 10.1002/cncr.26555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
263 Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 2013;717:58-66. [PMID: 23545358 DOI: 10.1016/j.ejphar.2013.02.057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
264 Gu G, Gelsomino L, Covington KR, Beyer AR, Wang J, Rechoum Y, Huffman K, Carstens R, Andò S, Fuqua SA. Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat 2015;150:535-45. [PMID: 25820519 DOI: 10.1007/s10549-015-3354-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
265 Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012;17:891-9. [PMID: 22584436 DOI: 10.1634/theoncologist.2012-0039] [Cited by in Crossref: 92] [Cited by in F6Publishing: 72] [Article Influence: 9.2] [Reference Citation Analysis]
266 Jr GR, Canton ED, Vega ML, Greco M, Sr GR, Valsecchi ME. Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol 2014; 5(3): 440-454 [PMID: 25114858 DOI: 10.5306/wjco.v5.i3.440] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
267 Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Di Filippo S, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Di Lauro L, Sanguineti G, Di Benedetto A, Giordano A, Vici P. Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. J Cell Physiol 2016;231:2541-7. [PMID: 27187274 DOI: 10.1002/jcp.25432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
268 Maréchal R, Demols A, Van Laethem JL. Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer. Drugs Aging 2013;30:155-65. [PMID: 23338795 DOI: 10.1007/s40266-013-0049-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
269 Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, Geng C, Shao Z. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget 2015;6:18683-92. [PMID: 26084292 DOI: 10.18632/oncotarget.4337] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
270 Smith IE, Kotsori A. Designing adjuvant treatment based on biological measurements in the neoadjuvant setting. Breast Cancer Res 2010;12 Suppl 4:S16. [PMID: 21172078 DOI: 10.1186/bcr2745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
271 Fayanju OM, Nwaogu I, Jeffe DB, Margenthaler JA. Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator. Mol Clin Oncol 2015;3:775-80. [PMID: 26171178 DOI: 10.3892/mco.2015.535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
272 Selitrennik M, Lev S. PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop. Oncotarget 2015;6:22214-26. [PMID: 26084289 DOI: 10.18632/oncotarget.4257] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
273 Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat 2013;137:471-82. [PMID: 23239151 DOI: 10.1007/s10549-012-2369-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
274 Ceugnart L, Coudert B, Dalenc F, Guinebretiere J, Rouanet P, Toledano A. Les traitements néoadjuvants (hors cancer du sein inflammatoire). Oncologie 2011;13:658-80. [DOI: 10.1007/s10269-011-2075-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
275 Oba T, Maeno K, Takekoshi D, Ono M, Ito T, Kanai T, Ito KI. Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer. BMC Cancer 2020;20:160. [PMID: 32106833 DOI: 10.1186/s12885-020-6647-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Salmon R, Ceugnart L, Selz J, Hennequin C, Ettore F, Gonçalves A. Les traitements néoadjuvants TNA (RPC 2013). Oncologie 2013;15:607-34. [DOI: 10.1007/s10269-013-2348-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
277 Fayanju OM, Ren Y, Suneja G, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Force J, Hyslop T, Hwang ES. Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. Int J Radiat Oncol Biol Phys 2020;106:377-89. [PMID: 31678225 DOI: 10.1016/j.ijrobp.2019.10.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
278 Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget 2017;8:12417-32. [PMID: 27926493 DOI: 10.18632/oncotarget.13778] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
279 Damodaran S, Olson EM. Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995) 2012;40:7-15. [PMID: 23299030 DOI: 10.3810/hp.2012.10.997] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
280 Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705-2713. [PMID: 24129232 DOI: 10.1038/bjc.2013.634] [Cited by in Crossref: 186] [Cited by in F6Publishing: 177] [Article Influence: 20.7] [Reference Citation Analysis]
281 Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci 2020;77:1571-89. [PMID: 31650186 DOI: 10.1007/s00018-019-03340-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
282 Mandish SF, Gaskins JT, Yusuf MB, Amer YM, Eldredge-Hindy H. The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response. Acta Oncol 2020;59:1210-7. [PMID: 32716227 DOI: 10.1080/0284186X.2020.1797161] [Reference Citation Analysis]
283 Zhu Q, Tannenbaum S, Kurtzman SH, DeFusco P, Ricci A Jr, Vavadi H, Zhou F, Xu C, Merkulov A, Hegde P, Kane M, Wang L, Sabbath K. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters. Breast Cancer Res 2018;20:56. [PMID: 29898762 DOI: 10.1186/s13058-018-0975-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
284 Hobbs EA, Hurvitz SA. New directions in the neoadjuvant treatment of HER2+ breast cancer. Breast Cancer Management 2015;4:223-34. [DOI: 10.2217/bmt.15.12] [Reference Citation Analysis]
285 Fosker C, Adlard JW, Shaaban A. Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet? Drugs 2011;71:1947-55. [PMID: 21985164 DOI: 10.2165/11595110-000000000-00000] [Reference Citation Analysis]
286 Gao Z, Xu J, Wang Y, Wu J, Sun T. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant. Front Oncol 2021;11:715554. [PMID: 34722261 DOI: 10.3389/fonc.2021.715554] [Reference Citation Analysis]
287 Cheng S, Huang Y, Lou C, He Y, Zhang Y, Zhang Q. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation. Cancer Biol Ther 2019;20:328-37. [PMID: 30336071 DOI: 10.1080/15384047.2018.1529101] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
288 Prior L, Lim M, Ward C, Featherstone H, Murray H, D'Arcy C, Crown J, Gullo G. Metastatic HER2+ Breast Cancer: A Potentially Curable Disease? Cureus 2017;9:e1654. [PMID: 29142802 DOI: 10.7759/cureus.1654] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
289 Ye Q, Qi F, Bian L, Zhang SH, Wang T, Jiang ZF. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer. Chin Med J (Engl) 2017;130:522-9. [PMID: 28229982 DOI: 10.4103/0366-6999.200542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
290 Morales S, Gasol A, Sanchez DR. Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. Cancers (Basel) 2021;13:5771. [PMID: 34830927 DOI: 10.3390/cancers13225771] [Reference Citation Analysis]
291 Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res 2017;19:16. [PMID: 28183321 DOI: 10.1186/s13058-017-0806-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
292 Yang C, Fan S, Wang X, Liu W, Yang L, He B, Dai W, Zhang H, Wang X, Zhang Q. Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin. Asian Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ajps.2022.06.002] [Reference Citation Analysis]
293 Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373. [PMID: 21768458 DOI: 10.1200/jco.2011.35.0868] [Cited by in Crossref: 493] [Cited by in F6Publishing: 222] [Article Influence: 44.8] [Reference Citation Analysis]
294 Ballard W, Vader J. Prevention of Cardiotoxicity in the Cancer Patient. Curr Cardiovasc Risk Rep 2017;11. [DOI: 10.1007/s12170-017-0558-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
295 Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol 2019;5:45-50. [PMID: 30193295 DOI: 10.1001/jamaoncol.2018.3691] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
296 Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011;2011:941876. [PMID: 20981352 DOI: 10.1155/2011/941876] [Cited by in Crossref: 122] [Cited by in F6Publishing: 130] [Article Influence: 10.2] [Reference Citation Analysis]
297 Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel C, Ro J. BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. Cancer Res Treat 2019;51:1527-39. [PMID: 31163957 DOI: 10.4143/crt.2018.598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs 2017;77:1313-36. [PMID: 28616845 DOI: 10.1007/s40265-017-0774-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
299 Kim DY, Park MS, Youn JC, Lee S, Choi JH, Jung MH, Kim LS, Kim SH, Han S, Ryu KH. Development and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO-RADIAT Score. J Am Heart Assoc 2021;10:e021931. [PMID: 34369199 DOI: 10.1161/JAHA.121.021931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
300 Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, Liu D, Wang S. HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients. Onco Targets Ther 2013;6:341-7. [PMID: 23630425 DOI: 10.2147/OTT.S40851] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
301 Li R, Hu S, Chang Y, Zhang Z, Zha Z, Huang H, Shen G, Liu J, Song L, Wei W. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells. Int J Mol Sci 2016;17:563. [PMID: 27092488 DOI: 10.3390/ijms17040563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
302 Buzatto IP, Ribeiro-Silva A, Andrade JM, Carrara HH, Silveira WA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Braz J Med Biol Res 2017;50:e5674. [PMID: 28146217 DOI: 10.1590/1414-431X20165674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
303 Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22:515-23. [PMID: 20603440 DOI: 10.1093/annonc/mdq345] [Cited by in Crossref: 293] [Cited by in F6Publishing: 254] [Article Influence: 24.4] [Reference Citation Analysis]
304 Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M. Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. Croat Med J 2015;56:128-38. [PMID: 25891872 DOI: 10.3325/cmj.2015.56.128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
305 Huober J, von Minckwitz G. Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years? Breast Care (Basel) 2011;6:419-26. [PMID: 22419894 DOI: 10.1159/000335347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
306 . Bibliography. Current world literature. Curr Opin Obstet Gynecol 2011;23:58-63. [PMID: 21191271 DOI: 10.1097/GCO.0b013e3283432017] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
307 Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol 2021;39:1485-505. [PMID: 33507815 DOI: 10.1200/JCO.20.03399] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 26.0] [Reference Citation Analysis]
308 McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. J Oncol 2016;2016:4324863. [PMID: 27382369 DOI: 10.1155/2016/4324863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
309 Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 2016;1:e000073. [PMID: 27843627 DOI: 10.1136/esmoopen-2016-000073] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
310 Yuan JQ, Ding NH, Xiao Z. The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients. Front Pharmacol 2020;11:537265. [PMID: 32973536 DOI: 10.3389/fphar.2020.537265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Barnadas A. Neoadjuvant treatment in young women with breast cancer. Breast Cancer Res Treat 2010;123 Suppl 1:35-8. [PMID: 20711668 DOI: 10.1007/s10549-010-1040-7] [Reference Citation Analysis]
312 Hayashi M, Kai K, Okumura Y, Osako T, Arima N, Iwase H, Nishimura R. Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy. Oncol Lett 2011;2:303-8. [PMID: 22866081 DOI: 10.3892/ol.2011.232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
313 Al-Sadawi M, Singh K, Capric V, Mohiuddin A, Haddadin M, Nunez A, Shaikh S, Bukharovich I, McFarlane SI. Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations. Int J Clin Res Trials 2020;5:154. [PMID: 33511317 DOI: 10.15344/2456-8007/2020/154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Res Treat. 2019;173:455-463. [PMID: 30328048 DOI: 10.1007/s10549-018-4990-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
315 Singh JC, Lichtman SM. Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs Aging 2021;38:829-44. [PMID: 34423398 DOI: 10.1007/s40266-021-00889-9] [Reference Citation Analysis]
316 Kim J, Lee J, Chang E, Suh K, Lee C, Jee J, Shin H. Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data. J Breast Cancer 2011;14:39-45. [PMID: 21847393 DOI: 10.4048/jbc.2011.14.1.39] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
317 Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 2021;22:1139-50. [PMID: 34339645 DOI: 10.1016/S1470-2045(21)00288-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
318 Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget 2018;9:6872-82. [PMID: 29467936 DOI: 10.18632/oncotarget.23914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
319 Cordero A, Ramsey MD, Kanojia D, Fares J, Petrosyan E, Schwartz CW, Burga R, Zhang P, Rashidi A, Castro B, Xiao T, Lee-Chang C, Miska J, Balyasnikova IV, Ahmed AU, Lesniak MS. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer. Proc Natl Acad Sci U S A 2022;119:e2112491119. [PMID: 34969858 DOI: 10.1073/pnas.2112491119] [Reference Citation Analysis]
320 Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol 2016;2:508-16. [PMID: 26720612 DOI: 10.1001/jamaoncol.2015.4935] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 9.5] [Reference Citation Analysis]
321 Irelli A, Parisi A, D'Orazio C, Sidoni T, Rotondaro S, Patruno L, Pavese F, Bafile A, Resta V, Pizzorno L, Ciuffetelli V, Dal Mas A, Calvisi G, Di Sibio A, Marzullo A, Zelli V, Compagnoni C, Tessitore A, Alesse E, Ficorella C, Cortellini A, Cannita K. Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers (Basel) 2022;14:3003. [PMID: 35740668 DOI: 10.3390/cancers14123003] [Reference Citation Analysis]
322 Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, O'Mahony K, Hammond L, Silva N, McDonnell D, Ballot J, Quinn C, McDermott EW, Evoy D, Prichard R, Geraghty J, Amstrong J, Crown J. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project. Br J Cancer 2018;119:374-80. [PMID: 29773838 DOI: 10.1038/s41416-018-0114-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
323 Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M, Hindié E. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer 2013;109:1157-64. [PMID: 23942075 DOI: 10.1038/bjc.2013.469] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
324 Shi Q, Wang J, Ai X, Xuhong J, Ma D, Zhang Y, Qi X, Jiang J. Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer. Gland Surg 2021;10:2255-65. [PMID: 34422596 DOI: 10.21037/gs-21-392] [Reference Citation Analysis]
325 Hurvitz SA, Kakkar R. Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012;4:35-51. [PMID: 24367193 DOI: 10.2147/BCTT.S29996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
326 Cazzaniga M, Bonanni B. Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012;2012:985620. [PMID: 22851887 DOI: 10.1155/2012/985620] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
327 Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol 2013;18:598-606. [PMID: 22833344 DOI: 10.1007/s10147-012-0437-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
328 Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, Tang Z, Wang Y, Su X, Li H, Yang G, Liu S. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Res Treat 2018;170:35-43. [PMID: 29480449 DOI: 10.1007/s10549-018-4730-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
329 Wang L, Hong Y, Ma J, Han M, Zhang S, Shan B, Liu Y. Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis. J Int Med Res 2020;48:300060520944310. [PMID: 32776809 DOI: 10.1177/0300060520944310] [Reference Citation Analysis]
330 Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, Cristofanilli M, Buchholz T, Gonzalez-Angulo AM. Survival of women with inflammatory breast cancer: a large population-based study. Ann Oncol 2014;25:1143-51. [PMID: 24669011 DOI: 10.1093/annonc/mdu121] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
331 Sbitti Y, Essaidi I, Debbagh A, Kadiri H, Oukabli M, Moussaid Y, Slimani K, Fetohi M, Elkaoui H, Albouzidi A, Mahi M, Ali AA, Ichou M, Errihani H. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol 2011;9:112. [PMID: 21955806 DOI: 10.1186/1477-7819-9-112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
332 Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Ali BA, Ibrahim M, Rimawi D. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther 2018;11:2091-6. [PMID: 29695917 DOI: 10.2147/OTT.S151821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
333 Ben Dhia S, Loap P, Loirat D, Vincent-Salomon A, Cao K, Escalup L, Fourquet A, Kirova Y. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity]. Cancer Radiother 2021;25:424-31. [PMID: 33771453 DOI: 10.1016/j.canrad.2020.06.037] [Reference Citation Analysis]
334 Zhang H, Ma G, Du S, Sun J, Zhang Q, Yuan B, Luo X. Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: a SEER population-based study. PeerJ 2019;7:e7659. [PMID: 31576238 DOI: 10.7717/peerj.7659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
335 Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 2015;20:94-104. [PMID: 25561512 DOI: 10.1634/theoncologist.2014-0342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
336 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47. [PMID: 21709140 DOI: 10.1093/annonc/mdr304] [Cited by in Crossref: 2110] [Cited by in F6Publishing: 1938] [Article Influence: 191.8] [Reference Citation Analysis]
337 Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad B, Li YC, Wang ZL, Li HY, Wu KN, Kong LQ. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis. Ther Clin Risk Manag 2018;14:1789-97. [PMID: 30310287 DOI: 10.2147/TCRM.S176214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
338 Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol 2020;50:3-11. [PMID: 31821506 DOI: 10.1093/jjco/hyz119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
339 Koo T, Kim IA. Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J 2016;34:1-9. [PMID: 27104161 DOI: 10.3857/roj.2016.34.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
340 Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24:1526-1533. [PMID: 23463626 DOI: 10.1093/annonc/mdt036] [Cited by in Crossref: 93] [Cited by in F6Publishing: 82] [Article Influence: 10.3] [Reference Citation Analysis]
341 Takahashi K, Nakagomi H, Inoue M, Nakayama Y, Furuya K, Maruyama M, Takano A, Sugai H, Hada M, Miyasaka Y, Amemiya K, Oyama T. Life-threatening metastasis was suppressed by trastuzumab containing regimen in a patient with Her2-negative breast cancer. Int Cancer Conf J 2016;5:61-5. [PMID: 31149426 DOI: 10.1007/s13691-015-0228-4] [Reference Citation Analysis]
342 Abe S, Yamamoto K, Kurata M, Abe-Suzuki S, Horii R, Akiyama F, Kitagawa M. Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. Oncotarget 2015;6:34892-909. [PMID: 26430873 DOI: 10.18632/oncotarget.5408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
343 Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. J Carcinog 2019;18:5. [PMID: 31949426 DOI: 10.4103/jcar.JCar_14_19] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
344 Fokter Dovnik N, Dovnik A, Čas Sikošek N, Ravnik M, Arko D, Takač I. Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis. Breast Care (Basel) 2016;11:406-10. [PMID: 28228707 DOI: 10.1159/000454690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
345 von der Heyde S, Wagner S, Czerny A, Nietert M, Ludewig F, Salinas-Riester G, Arlt D, Beißbarth T. mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer. PLoS One 2015;10:e0117818. [PMID: 25710561 DOI: 10.1371/journal.pone.0117818] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
346 McGuire A, Casey MC, Waldron RM, Heneghan H, Kalinina O, Holian E, McDermott A, Lowery AJ, Newell J, Dwyer RM, Miller N, Keane M, Brown JAL, Kerin MJ. Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers (Basel) 2020;12:E1820. [PMID: 32645898 DOI: 10.3390/cancers12071820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
347 Agarwal R, Unnikrishnan UG, Keechilat P, Rajanbabu A, Jose W, Vijaykumar DK. Pathological Complete Response in Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy: Survival Outcome and Its Relevance as a Surrogate End Point. South Asian J Cancer 2020;9:136-40. [PMID: 33937135 DOI: 10.1055/s-0040-1721238] [Reference Citation Analysis]
348 Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 2014;25:592-8. [PMID: 24401928 DOI: 10.1093/annonc/mdt543] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 7.8] [Reference Citation Analysis]
349 Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2014;41:1525-33. [PMID: 24647576 DOI: 10.1007/s00259-014-2739-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
350 Foulon A, Theret P, Rodat-Despoix L, Kischel P. Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. Cancers (Basel) 2020;12:E2634. [PMID: 32947780 DOI: 10.3390/cancers12092634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
351 Jafri M, Rea D. Cardiac safety of simultaneous anti-HER2 and anthracycline therapy. Breast Cancer Management 2016;5:21-9. [DOI: 10.2217/bmt.16.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
352 Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 2014;15:e42-50. [PMID: 24384493 DOI: 10.1016/S1470-2045(13)70334-6] [Cited by in Crossref: 141] [Cited by in F6Publishing: 93] [Article Influence: 17.6] [Reference Citation Analysis]
353 Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 2012;26:447-81, vii. [PMID: 22520975 DOI: 10.1016/j.hoc.2012.02.013] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
354 Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Prat A, Ribelles N, Alba E. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. Front Oncol 2019;9:1178. [PMID: 31750258 DOI: 10.3389/fonc.2019.01178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
355 Kristeleit H, Parton M, Beresford M, Macpherson IR, Sharma R, Lazarus L, Kelleher M. Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Target Oncol 2016;11:579-91. [PMID: 27181019 DOI: 10.1007/s11523-016-0438-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
356 Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, Vici P. Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. J Clin Med 2019;8:E254. [PMID: 30781624 DOI: 10.3390/jcm8020254] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
357 Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. Ann Surg Oncol 2017;24:3502-9. [PMID: 28726077 DOI: 10.1245/s10434-017-6009-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
358 Cai H, Shukla S, Wang C, Masarapu H, Steinmetz NF. Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine. J Am Chem Soc 2019;141:6509-18. [PMID: 30995022 DOI: 10.1021/jacs.9b01523] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
359 Zhao CL, Singh K, Brodsky AS, Lu S, Graves TA, Fenton MA, Yang D, Sturtevant A, Resnick MB, Wang Y. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. BMC Cancer 2019;19:1036. [PMID: 31675929 DOI: 10.1186/s12885-019-6134-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
360 Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL, Macià M, Corominas JM, Delgado-Rodriguez M, Gonzalez L, Albanell J, Fernández M, Solé F, Lorente JA, Serrano MJ. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 2012;14:R71. [PMID: 22554015 DOI: 10.1186/bcr3180] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
361 Gonçalves A. [Not Available]. Bull Cancer 2016;103:S76-89. [PMID: 27494978 DOI: 10.1016/S0007-4551(16)30149-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
362 Puglisi F, Minisini AM, De Angelis C, Arpino G. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. Drugs 2012;72:1175-93. [PMID: 22686613 DOI: 10.2165/11634000-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
363 Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clin Cancer Res 2021;27:6156-63. [PMID: 34465600 DOI: 10.1158/1078-0432.CCR-21-2103] [Reference Citation Analysis]
364 Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018;29:646-53. [PMID: 29253081 DOI: 10.1093/annonc/mdx773] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 17.0] [Reference Citation Analysis]
365 Kourie HR, El Rassy E, Clatot F, de Azambuja E, Lambertini M. Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. Onco Targets Ther 2017;10:3363-72. [PMID: 28744140 DOI: 10.2147/OTT.S122397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
366 Mandilaras V, Bouganim N, Spayne J, Dent R, Arnaout A, Boileau JF, Brackstone M, Meterissian S, Clemons M. Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm? Curr Oncol 2015;22:25-32. [PMID: 25684986 DOI: 10.3747/co.21.2043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
367 Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 2013;24:1999-2004. [PMID: 23562929 DOI: 10.1093/annonc/mdt131] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
368 Witkiewicz AK, Balaji U, Knudsen ES. Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res 2014;20:4837-48. [PMID: 25047707 DOI: 10.1158/1078-0432.CCR-14-0885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
369 Sevcikova K, Vertakova-Krakovska B, Spanik S. Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer. ISRN Oncol 2013;2013:362467. [PMID: 23762609 DOI: 10.1155/2013/362467] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
370 Chen X, Ye G, Zhang C, Li X, Shen K. Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study. Chin J Cancer Res 2016;28:561-9. [PMID: 28174484 DOI: 10.21147/j.issn.1000-9604.2016.06.02] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
371 Liu S, Mou E, Zeng S, Wang L, Dong H, Ji J, Yang H, Li J, Wang H, Li H, Xu J. Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes. Cancer Manag Res 2020;12:3145-53. [PMID: 32440212 DOI: 10.2147/CMAR.S248071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
372 Zhang W, Pan Z, Yuan Y. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data. J Biopharm Stat 2022;:1-14. [PMID: 35679137 DOI: 10.1080/10543406.2022.2080700] [Reference Citation Analysis]
373 Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, Suneja G, Devi GR, King TA, Nakhlis F, Hyslop T, Hwang ES. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat 2020;180:207-17. [PMID: 31960171 DOI: 10.1007/s10549-020-05529-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]